Technical Analysis for AGE - AgeX Therapeutics, Inc.

Grade Last Price % Change Price Change
grade F 2.48 -0.80% -0.02
AGE closed down 0.8 percent on Tuesday, September 17, 2019, on 69 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent N/A Down Down
See historical AGE trend table...

Date Alert Name Type % Chg
Doji - Bullish? Reversal 0.00%
Down 3 Days in a Row Weakness 0.00%
Down 4 Days in a Row Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
MACD Bearish Signal Line Cross Bearish -0.80%
Spinning Top Other -0.80%
Narrow Range Bar Range Contraction -0.80%
NR7 Range Contraction -0.80%
Stochastic Reached Oversold Weakness -0.80%

Older signals for AGE ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
AgeX is a biotechnology company focused on the development of novel therapeutics for age-related degenerative disease. AgeX’s mission is to apply the proprietary technology platform related to telomerase-mediated cell immortality and regenerative biology to address a broad range of diseases of aging. The current preclinical development efforts include two cell-based therapies derived from telomerase-positive pluripotent stem cells and two product candidates derived from the company’s proprietary induced Tissue Regeneration (iTR™) technology. AGEX-BAT1 and AGEX-VASC1 are cell-based approaches in the preclinical stage of development comprised of young regenerative cells modified using AgeX’s UniverCyte™ technology facilitating immune tolerance, formulated in HyStem® matrix, designed to correct metabolic imbalances in aging and to restore vascular support in ischemic tissues respectively. AGEX-iTR1547 is a drug-based formulation in preclinical development intended to restore regenerative potential in a wide array of aged tissues afflicted with degenerative disease using the company’s proprietary iTR technology. Renelon™ is a first-generation iTR product designed to promote scarless tissue repair which AgeX plans to initially develop as a topically-administered device for commercial development through a 510(k) application. In addition to the product candidates in early development, AgeX, through its LifeMap subsidiary, currently markets genomic interpretation algorithms. AgeX also markets Cytiva® comprised of PSC-derived heart muscle cells used in screening drugs for efficacy and safety.
Biotechnology Life Sciences Biology Diseases Stem Cells Cell Biology Tissue Engineering Degenerative Disease Cloning Stem Cell Telomerase
Is AGE a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 5.95
52 Week Low 1.13
Average Volume 78,882
200-Day Moving Average 0.0
50-Day Moving Average 2.7442
20-Day Moving Average 2.6665
10-Day Moving Average 2.614
Average True Range 0.2242
ADX 11.64
+DI 13.3083
-DI 17.0592
Chandelier Exit (Long, 3 ATRs ) 2.4674
Chandelier Exit (Short, 3 ATRs ) 3.1126
Upper Bollinger Band 2.8757
Lower Bollinger Band 2.4573
Percent B (%b) 0.05
BandWidth 15.690981
MACD Line -0.0604
MACD Signal Line -0.0487
MACD Histogram -0.0117
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 2.66
Resistance 3 (R3) 2.67 2.61 2.63
Resistance 2 (R2) 2.61 2.57 2.61 2.62
Resistance 1 (R1) 2.55 2.54 2.52 2.54 2.61
Pivot Point 2.49 2.49 2.48 2.49 2.49
Support 1 (S1) 2.43 2.45 2.40 2.42 2.35
Support 2 (S2) 2.37 2.42 2.37 2.34
Support 3 (S3) 2.31 2.37 2.33
Support 4 (S4) 2.30